Inflammatory breast cancer: the disease, the biology, the treatment

Robertson, Fredika M. and Bondy, Melissa and Yang, Wei and Yamauchi, Hideko and Wiggins, Shannon and Kamrudin, Samira and Krishnamurthy, Savitri and Le-Petross, Huong and Bidaut, Luc and Player, Audrey N. and Barsky, Sanford H. and Woodward, Wendy A. and Buchholz, Thomas and Lucci, Anthony and Ueno, Naoto T. and Cristofanilli, Massimo (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA: a Cancer Journal for Clinicians, 60 (6). pp. 351-375. ISSN 0007-9235

Full content URL: https://doi.org/10.3322/caac.20082

Documents
24133 Robertson_et_al-2001-CA-_A_Cancer_Journal_for_Clinicians.pdf

Request a copy
[img] PDF
24133 Robertson_et_al-2001-CA-_A_Cancer_Journal_for_Clinicians.pdf - Whole Document
Restricted to Repository staff only

768kB
Item Type:Article
Item Status:Live Archive

Abstract

Inflammatory breast cancer (IBC) is a rare and aggressive form of invasive breast cancer accounting for 2.5 of all breast cancer cases. It is characterized by rapid progression, local and distant metastases, younger age of onset, and lower overall survival compared with other breast cancers. Historically, IBC is a lethal disease with less than a 5 survival rate beyond 5 years when treated with surgery or radiation therapy. Because of its rarity, IBC is often misdiagnosed as mastitis or generalized dermatitis. This review examines IBC's unique clinical presentation, pathology, epidemiology, imaging, and biology and details current multidisciplinary management of the disease, which comprises systemic therapy, surgery, and radiation therapy. ©2010 American Cancer Society, Inc.

Keywords:anthracycline, bevacizumab, carboplatin, chemokine receptor, cisplatin, cyclooxygenase 2, cyclophosphamide, cytokine, docetaxel, doxorubicin, epidermal growth factor receptor 2, epirubicin, fluorouracil, immunoglobulin enhancer binding protein, lapatinib, paclitaxel, pazopanib, prostanoid receptor, protein farnesyltransferase inhibitor, Rho C guanosine triphosphatase, Rho guanine nucleotide binding protein, semaxanib, somatomedin, tipifarnib, trastuzumab, tumor suppressor protein, unclassified drug, uvomorulin, Wnt inducible signaling protein 3, anamnesis, antineoplastic activity, body mass, breast cancer, breast carcinogenesis, breast reconstruction, cancer classification, cancer growth, cancer invasion, cancer radiotherapy, cancer staging, cancer stem cell, clinical feature, clinical trial, contrast enhancement, dermatitis, diagnostic accuracy, diagnostic error, differential diagnosis, drug efficacy, drug targeting, echomammography, epithelial mesenchymal transition, ethnic difference, family history, gene overexpression, heart function, histopathology, human, image analysis, inflammatory breast cancer, lymphangiogenesis, mammography, mastectomy, mastitis, metastasis, molecular interaction, multimodality cancer therapy, multiple cycle treatment, needle biopsy, nuclear magnetic resonance imaging, onset age, overall survival, physical examination, positron emission tomography, preoperative treatment, priority journal, prognosis, protein depletion, review, risk factor, sentinel lymph node biopsy, side effect, signal transduction, skin biopsy, tumor vascularization, Body Mass Index, Chemotherapy, Adjuvant, Combined Modality Therapy, Diagnosis, Differential, Disease Progression, Female, Humans, Incidence, Inflammatory Breast Neoplasms, Magnetic Resonance Imaging, Neoplasm Staging, Obesity, Positron-Emission Tomography, Radiotherapy, Adjuvant, Rare Diseases, Risk Assessment, Risk Factors, Survival Rate, Tomography, X-Ray Computed, Tumor Markers, Biological, Ultrasonography, Mammary, United States
Subjects:B Subjects allied to Medicine > B100 Anatomy, Physiology and Pathology
F Physical Sciences > F350 Medical Physics
Divisions:College of Science > School of Computer Science
Related URLs:
ID Code:24133
Deposited On:07 Apr 2017 13:28

Repository Staff Only: item control page